Fondazione IRCCS: Istituto Nazionale dei Tumori


Mailand (Milano), Italy

Publications in cooperation with FAU scientists

Go to first page Go to previous page 1 of 3 Go to next page Go to last page
Heinzerling, L., Ascierto, P.A., Dummer, R., Gogas, H., Grob, J.-J., Lebbe, C.,... Hauschild, A. (2019). Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology. European journal of cancer, 112, 29-31.
Girard, N., Mornex, F., Christoph, D.C., Fietkau, R., Filippi, A.R., Field, J.,... Garassino, M.C. (2019). PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. In ANNALS OF ONCOLOGY. Geneva, CH: OXFORD: OXFORD UNIV PRESS.
Dork, T., Peterlongo, P., Mannermaa, A., Bolla, M.K., Wang, Q., Dennis, J.,... Geisler, J. (2019). Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 9(1).
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Larkin, P.J., Cherny, N.I., La Carpia, D., Guglielmo, M., Ostgathe, C., Scotte, F., & Ripamonti, C.I. (2018). Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 29(Supplement_4), iv111-iv125.
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Herbst, F., Ridolfi, A.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
Chan, D.L., Yao, J.C., Carnaghi, C., Buzzoni, R., Herbst, F., Ridolfi, A.,... Singh, S. (2018). Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 151-151).
Lopez-Isac, E., Bossini-Castillo, L., Palma, A.B., Assassi, S., Mayes, M.D., Simeon, C.P.,... Martin, J. (2017). Analysis of ATP8B4 F436L missense variant in a large Systemic sclerosis cohort. Arthritis and Rheumatology.
Kasper, B., Baumgarten, C., Garcia, J., Bonvalot, S., Haas, R., Haller, F.,... Gronchi, A. (2017). An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of Oncology, 28(10), 2399-2408.
Shimelis, H., Mesman, R.L.S., Von Nicolai, C., Ehlen, A., Guidugli, L., Martin, C.,... Couch, F.J. (2017). BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 77(11), 2789-2799.
Pavel, M.E., Singh, S., Strosberg, J.R., Bubuteishvili-Pacaud, L., Degtyarev, E., Neary, M.P.,... Yao, J.C. (2017). Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 18(10), 1411-1422.
Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F.,... Pommier, R. (2017). Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Oncotargets and Therapy, 10, 5013-5030.
Brouckaert, O., Rudolph, A., Laenen, A., Keeman, R., Bolla, M.K., Wang, Q.,... Neven, P. (2017). Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 19(1).
Huang, L., Jansen, L., Balavarca, Y., Molina-Montes, E., Babaei, M., Van Der Geest, L.,... Brenner, H. (2017). Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut.
Wyszynski, A., Hong, C.-C., Lam, K., Michailidou, K., Lytle, C., Yao, S.,... Cole, M.D. (2016). An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 25(17), 3863-3876.
Zhao, Z., Wen, W., Michailidou, K., Bolla, M.K., Wang, Q., Zhang, B.,... Zheng, W. (2016). Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes & Control, 27(5), 679-93.
Horne, H.N., Chung, C.C., Zhang, H., Yu, K., Prokunina-Olsson, L., Michailidou, K.,... Figueroa, J.D. (2016). Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 11(8).
Shi, J., Zhang, Y., Zheng, W., Michailidou, K., Ghoussaini, M., Bolla, M.K.,... Long, J. (2016). Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 139(6), 1303-1317.
Lei, J., Rudolph, A., Moysich, K.B., Behrens, S., Goode, E.L., Bolla, M.K.,... Chang-Claude, J. (2016). Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human genetics, 135(1), 137-54.
Easton, D.F., Lesueur, F., Decker, B., Michailidou, K., Li, J., Allen, J.,... Chenevix-Trench, G. (2016). No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 53(5), 298-309.

Last updated on 2015-09-12 at 12:14